Keyword: Northwest Biotherapeutics
Northwest Biotherapeutics has hired Kevin Duffy, Ph.D., who worked on Merck's PD-1 drug Keytruda from its early days through commercialization.
Northwest Bio unveiled interim phase 3 data showing its dendritic cell vaccine improved survival rates in patients with newly diagnosed glioblastoma.
The trials and tribulations of Northwest Bio involve allegations of subterfuge, the FBI, a star investor and some heavy questioning about its strange financial relationship with its contract manufacturer Cognate—not to mention confusion and delay over its cancer vaccine, delisting from the Nasdaq and penny stocks.
Welcome to our new annual feature that aims to name and shame those biopharmas and medical device companies that made an attempt at being ripe but turned out to be rotten.
The FDA has lifted the partial clinical hold on Northwest Biotherapeutics’ phase 3 cancer vaccine trial.
Neil Woodford, who has seen his light dim in 2016 as a “star fund manager”, signalled in a brief update with The Times that he was to stop investing in the moribund biotech NW Bio after seeing his original investment decimated.
Bethesda biotech Northwest Bio's troubles are far from over as Nasdaq finds it failed to comply with its rules.